Inter-Relationship Between Melanoma Vemurafenib Tolerance Thresholds and Metabolic Pathway Choice

Melanomas quickly acquire resistance to vemurafenib, an important therapeutic for BRAFV600 mutant melanomas. Although combating vemurafenib resistance (VemR) to counter mitochondrial metabolic shift using mitochondria-targeting therapies has promise, no studies have analyzed the relationship between...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Pratima Nangia-Makker, Madison Ahrens, Neeraja Purandare, Siddhesh Aras, Jing Li, Katherine Gurdziel, Hyejeong Jang, Seongho Kim, Malathy P Shekhar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2025-06-01
Edice:	Cells
Témata:	melanoma BRAF adaptive resistance RNA-seq metabolome Wnt signaling
On-line přístup:	https://www.mdpi.com/2073-4409/14/12/923
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!